

## Original Research Article

# Effect of *Prunella vulgaris* L extract on hyperplasia of mammary gland in rats

Yu-xian Qian<sup>1</sup>, Lin Wang<sup>2</sup>, Xuan Yang<sup>1</sup> and Xin-ke Li<sup>3\*</sup>

<sup>1</sup>Department of General surgery, Ningbo No. 9 Hospital, Ningbo 315020, Zhejiang Province, <sup>2</sup>Department of Gynaecology and Obstetrics, Wuhu No. 1 People's Hospital, Wuhu 241000, Anhui, <sup>3</sup>Intensive Care Unit, Ningbo No. 9 Hospital, Ningbo 315020, Zhejiang Province, China

\*For correspondence: **Email:** [lixinke133494@163.com](mailto:lixinke133494@163.com); **Tel:** +86-13819899617

Received: 31 July 2016

Revised accepted: 7 March 2017

### Abstract

**Purpose:** To explore the effects of *Prunella vulgaris* L extract (PVE) on hyperplasia of mammary gland (HMG) in rats.

**Methods:** Forty virgin female Wistar rats were randomly divided into normal group, control group (HMG model), positive control group (Rupixiao Capsule, RPXC), and low-, medium- and high-dose (150, 300 and 600 mg/kg) of PVE groups. Injections of estrogen and progesterone were given at the same time to prepare rat. Changes in nipple height were measured, while serum estradiol (E2), progesterone (P), prolactin (PRL), follicle stimulating hormone (FSH) and luteinizing hormone (LH) levels were evaluated by ELISA; Uterus and ovary indices were determined.

**Results:** Compared with control group, PVE reduced elevated nipple height to  $2.25 \pm 0.09$  mm ( $p < 0.01$ ) and uterus index to  $2.29 \pm 0.41$  mg/g ( $p < 0.01$ ), as well as reduced the number of mammary gland lobules and secretion in HMG rats. Compared with control group, serum E2 ( $2.81 \pm 0.17$  pmol/L), PRL ( $269.38 \pm 8.28$  pg/mL) and FSH ( $0.13 \pm 0.03$  IU/L) levels ( $p < 0.01$ ) were lowered, but serum P ( $1.31 \pm 0.13$  ng/mL) and LH ( $1.73 \pm 0.08$  mIU/mL) levels were higher ( $p < 0.01$ ) in rats treated with high-dose PVE.

**Conclusion:** These results suggest that PVE exerts anti-HMG effect in rats induced by estrogen and progesterone.

**Keywords:** *Prunella vulgaris* L; Anti-inflammatory; Anti-hyperplasia of mammary gland

Tropical Journal of Pharmaceutical Research is indexed by Science Citation Index (SciSearch), Scopus, International Pharmaceutical Abstract, Chemical Abstracts, Embase, Index Copernicus, EBSCO, African Index Medicus, JournalSeek, Journal Citation Reports/Science Edition, Directory of Open Access Journals (DOAJ), African Journal Online, Bioline International, Open-J-Gate and Pharmacy Abstracts

## INTRODUCTION

Hyperplasia of mammary gland (HMG) is a common disease in middle-aged women. It is a kind of pathological hyperplasia of lobules of mammary gland induced by balance disorder of estrogen and progesterone. The morbidity of HMG is increasing nowadays, with a risk of causing mammary carcinoma. Therefore, it is important to search for more convenient and effective new drugs with few side effects for treating hyperplasia of mammary glands as well as explore the anti-HMG mechanisms of these

drugs that would block its development into breast cancer [1].

HMG is related to menstrual cycle, breast-feeding, occupation, abuse of sex hormone drugs, diet and stress [2,3]. HMG patients have increased in number in recent years. Studies have shown that some Traditional Chinese Medicine products may improve regulatory mechanisms of the body that could inhibit HMG [4].

*Prunella vulgaris* L, is a herb from barley that is widely used in China. It is capable of regulating endocrine disorder and is frequently used in the treatment of HMG [5]. The aim of the present study was to examine the therapeutic effect of *Prunella vulgaris* L extract against hyperplasia of mammary gland in rats.

## EXPERIMENTAL

### Material

The herbal samples of were collected from Luoyang City, Henan Province in China in May 2015. Taxonomic identification of the plant was performed by Professor Lu Gan of Zhejiang University, in China. A voucher specimen of herbarium (no. PVE 201505027) was deposited in the herbarium of College of Pharmacy, Zhejiang University, China for future reference. The aqueous extract of *Prunella vulgaris* L was obtained by steeping the dried *Prunella vulgaris* L in water at 60 °C three times, for 1 hour on each occasion. Then it was dried in a oven and freeze-dried until obtained. The yield was 50.0 %.

### Animals

Virgin female Wistar rats weighing 200 – 240 g and Kunming female mice (18 - 22g) were provided by the Experimental Animal Center of Zhejiang Province (Certificate no. SYXK 2005-0002). The animals had free access to food and water, and were allowed to acclimatize for at least one week before use. The rat experiment was approved by Animal Care and Use Committee of Ningbo No. 9 Hospital (approval ref no. 20110605) and was carried out in compliance with Directive 2010/63/EU on the handling of animals used for scientific purposes [6].

### Animal groups

Rats were treated with estrogen (0.5 mg/kg) intra-muscularly for 25 days, followed by progestogen (5 mg/kg) for another 5 days to induce HMG model. The rats were randomly divided into 6 groups of ten rats: normal group, model group, positive group (Rupixiao Capsule, RPXC 400 mg/kg) as well as PVE groups (150, 300 and 600 mg/kg doses). From the 31st day, the rats in the normal group and model group received distilled water by gavage, the rats in RPXC group were treated with RPXC, and the rats in the PVE group were respectively administered PVE by intragastric administration. Treatments were given orally once daily for 4 weeks.

### Cotton pellet-induced granuloma

Sterile cotton pellets (10 mg) were implanted subcutaneously in groin of anesthetized mice (18 – 22 g). Ten animals were used for every treatment. The animals received 150, 300 and 600 mg/kg of PVE, RPXC (400 mg/kg) or saline (10 ml/kg) orally, once a day through an oral cannula over 7 consecutive days. On the 8th day, the mice were sacrificed and the cotton pellet removed, dried overnight at 60 °C and weighed. The increase in weight of cotton pellet was determined and used for further calculation.

### Determination of nipple height and biochemical assay

The nipple height of all rats were measured after the treatment. The contents of sex hormones - E2, P, PRL, FSH and LH - were determined using ELISA kits (Nanjing Jiancheng Co Ltd, China). Uterus index was calculated as uterus weight divided by body weight, while ovary index derived as the ratio of ovary weight to body weight.

### Statistical analysis

Values are expressed as mean  $\pm$  SEM. Multiple group comparisons were performed using one-way analysis of variance (ANOVA) followed by Dunnett's test to detect intergroup differences.  $P < 0.05$  was considered statistically significant in all cases.

## RESULTS

### Cotton pellet-induced granuloma

The results revealed that PVE significantly inhibited the dried weight of the cotton pellet granuloma in a dose-dependent manner. The values for doses of 150, 300 and 600 mg/kg PVE were 18.15, 22.24 and 28.14 %, respectively. RPXC inhibited granuloma tissue formation by 17.21 %, which is lower than that observed for 100 mg/kg dose of PVE. Thus, PVE significantly suppressed granulomatous tissue formation during chronic inflammation (Table 1).

### Effect of PVE on rat nipple height

The height of nipples (right 2 and right 3) of rats was significantly decreased by RPXC (400 mg/kg) and PVE (600 mg/kg) treatments compared with HMG control group ( $p < 0.01$ , Table 2).

**Table 1:** Effect of PVE in mice cotton pellet-induced inflammation

Group	Dose (mg/kg)	Granuloma weight (mg)	Inhibition rate (%)	P-value
Normal	—	72.36 ± 8.41		
RPXC	400	64.24 ± 11.56	16.68	> 0.05
PVE-L	150	62.12 ± 15.78	19.26	> 0.05
PVE-M	300	57.28 ± 13.35	24.35	< 0.05
PVE-H	600	55.76 ± 12.29	27.29	< 0.05

\* $P < 0.05$ , \*\* $p < 0.01$  vs model group; PVE-L: low-dose of PVE; PVE-M: middle-dose of PVE; PVE-H: high-dose of PVE; RPXC: Rupixiao Capsule

**Table 2:** Effect of PVE on nipple height in rats

Group	Dosage (mg/kg)	Nipple height (mm)	
		Right 2	Right 3
Normal	—	1.62 ± 0.15**	1.63 ± 0.16**
Control	—	2.79 ± 0.27	2.64 ± 0.21
RPXC	400	2.24 ± 0.23**	2.34 ± 0.12**
PVE-H	600	1.93 ± 0.08**	2.25 ± 0.09**

\* $P < 0.05$ , \*\* $p < 0.01$  vs model group; PVE-H: high-dose of PVE; RPXC: Rupixiao Capsule

**Table 3:** Effect of PVE on serum sex hormone levels in rats

Group	Dosage (mg/kg)	E2 (pmol/L)	P (ng/mL)	PRL (pg/mL)	FSH (IU/L)	LH (mIU/mL)
Normal	—	2.85±0.38*	1.45±0.17*	275.46±6.48	0.12±0.02	1.92±0.09
Model	—	4.65±0.16	0.72±0.08	398.54±8.26	0.58±0.02	1.12±0.05
RPXC	400	3.36±0.24*	1.22±0.15*	423.23±12.34	0.47±0.19	1.42±0.10*
PVE-H	600	2.81±0.17**	1.31±0.13**	269.38±8.28**	0.13±0.03**	1.73±0.08

\* $P < 0.05$ , \*\* $p < 0.01$  vs. model group; PVE-H: high-dose of PVE; RPXC: Rupixiao Capsule

### Effect of PVE on rat serum sex hormone levels

After injection of estrogen and progesterone, E2, PRL and FSH contents were significantly increased, while P and LH levels decreased in HMG control rats. E2, PRL and FSH were decreased by PVE (600 mg/kg) treatment compared with model group ( $p < 0.01$ ), P and LH contents were remarkably increased compared to HMG control group ( $p < 0.01$ ) (Table 3).

### Effect of PVE on uterus and ovary index in rats

Uterus index in HMG model rats were significantly increased compared with normal group ( $p < 0.01$ ). Uterus index was significantly decreased by RPXC (400 mg/kg) ( $p < 0.01$ ) and PVE (600 mg/kg) ( $p < 0.05$ ) treatment as compared with HMG model group. Ovary index was not shown distinct difference compared with control group (Table 4).

## DISCUSSION

There is evidence that chronic inflammation brought about by persistent chemical, bacterial or viral agents is a risk factor for cancer [7-10]. Inflammation by innate immunity, which is

required to fight microbial infections, heal wounds and maintain tissue homeostasis, can lead to cancer [11-13].

**Table 4:** Effects of PVE on uterus and ovary index in rats

Group	Dosage (mg/kg)	Uterus index (mg/g)	Ovary index (mg/g)
Normal	—	2.23 ± 0.36	0.82 ± 0.08
Model	—	2.87 ± 0.41	0.52 ± 0.12
RPXC	400	2.35 ± 0.24**	0.47 ± 0.06
PVE-H	600	2.29 ± 0.41*	0.45 ± 0.06

\* $P < 0.05$ , \*\* $p < 0.01$  vs model group; PVE-H: high-dose of PVE; RPXC: Rupixiao Capsule

Several recent studies have suggested that inflammation has an important role in all phases of tumor development, including tumor initiation, tumor promotion, invasion, metastatic dissemination, and evasion of immune system [14]. The development of many types of cancer including breast cancer is related to inflammation.

Epidemiological studies have revealed that the use of non-steroidal anti-inflammatory drugs can decrease the risk of developing breast cancer [15,16]. The study revealed that PVE-H had strong anti-inflammatory activities in chronic inflammation model mice. The inflammatory

granuloma is a typical feature of a chronic inflammatory process. The dried weight of the pellets correlates with the amount of granulomatous tissue. Therefore, cotton pellet granuloma method has been widely used to evaluate the proliferative components of chronic inflammation.

In the present study, PVE inhibited chronic proliferative inflammation processes with a dose-dependent inhibition of granuloma formation in mice, and also has ameliorative effects in HMG rats induced by estrogen and progesterone. The heights of nipples of rats were significantly decreased by PVE-H treatment compared with control. Results showed that uterus index were remarkably decreased by PVE-H treatment compared with HMG model group. Ovary index was not shown distinct difference compared with control group. After administration of PVE-H in HMG rats, E2, PRL and FSH were remarkably decreased, while P and LH significantly increased in relation to control.

## CONCLUSION

The findings of this study demonstrate that PVE significantly inhibits mammary gland hyperplasia in rats. Therefore, the plant has the potential to be developed as a treatment of HMG in patients.

## DECLARATIONS

### Acknowledgement

None declared

### Conflict of Interest

No conflict of interest associated with this work.

### Contribution of Authors

The authors declare that this work was done by the authors named in this article and all liabilities pertaining to claims relating to the content of this article will be borne by them.

### Open Access

This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>) and the Budapest Open Access Initiative (<http://www.budapestopenaccessinitiative.org/read>), which permit unrestricted use, distribution,

and reproduction in any medium, provided the original work is properly credited.

## REFERENCES

1. Li GY, Liu JZ, Chen SG, Wang CB, Wang LX. Effect of a seashell protein Haishengsu on the immunological function of mice with Ehrlich ascites tumor. *Immunopharmacol. Immunotoxicol.* 2009; 31: 669–674.
2. Xu KY. The etiology and clinical intervention of hyperplasia of mammary glands. *China Prac Med* 2011; 6: 99.
3. Xu W, Chang Z, Liu X, Jiang C, Xu L. Antitumor effects of a polypeptide isolated from *Tegillarca granosa linnaeus* and the related molecular mechanism. *Pak J. Pharm Sci.* 2014; 27: 565–570.
4. Qian LQ. Clinical observation on treatment of hyperplasia of mammary gland by Lirukang Granule. *Chin J Integ Med* 2007; 13: 120-124.
5. Yang HZ, Lin BS. The curative effect observation of *Prunella vulgaris* L extract on 92 hyperplasia of mammary gland patients. *Guide of China Med* 2013; 8: 34-36.
6. European Commission [homepage on the internet]. Directive 2010/63/EU on the protection of animals used for scientific purposes [cited 2013 Jan 16]. Available from: [http://ec.europa.eu/environment/chemicals/lab\\_animals/egislation\\_en.htm](http://ec.europa.eu/environment/chemicals/lab_animals/egislation_en.htm).
7. Hussain SP, Harris CC. Inflammation and cancer: an ancient link with novel potentials. *Int J Cancer* 2007; 121: 2373-2380.
8. Mantovani A. Cancer-related inflammation. *Nature* 2008; 454: 436-444.
9. Mantovani A. Molecular pathways linking inflammation and cancer. *Curr Mol Med* 2010; 10: 369-373.
10. Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. *J Clin Invest* 2007; 117: 1175-1183.
11. Trinchieri G. Inflammation in cancer: a therapeutic target? *Oncology (Williston Park)* 2011; 25: 418-420.
12. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell* 2011; 144: 646-674.
13. Chang ZL. Important aspects of Toll-like receptors, ligands and their signaling pathways. *Inflammation Research* 2010; 59: 791-808.
14. Trinchieri G. Cancer and inflammation: an old intuition with rapidly evolving new concepts. *Annu Rev Immunol* 2012; 30: 677–706.
15. Howe LR. HER2/neu-induced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice. *Cancer Res* 2005; 65: 10113-10119.
16. Reed JR. Interleukin-1 beta and fibroblast growth factor receptor 1 cooperate to induce cyclooxygenase-2 during early mammary tumorigenesis. *Breast Cancer Res* 2009; 11: 21-23.